Chris Boerner, Board Chair and Chief Executive Officer at Bristol Myers Squibb, shared a post on LinkedIn:
“$40 billion over the next five years.
This investment by Bristol Myers Squibb is a commitment to advancing RnD, technology and manufacturing across the U.S. And it’s a commitment to bringing new hope to patients, supporting local jobs and driving progress in healthcare.
As someone who has spent most of my career in oncology, I’ve witnessed tremendous progress in cancer care, leading to better survival rates, improved quality of life and more effective treatments. One of the most exciting breakthroughs today is in radiopharmaceutical therapy (RPT) – a major step forward in precision oncology. These complex treatments are a testament to our dedication to scientific innovation and hold great promise for improving patient outcomes.
One example of our BMS investment commitment is a state-of-the-art facility in Indianapolis that is working to bring this incredible potential to life. We are proud to own and operate this first-of-its-kind RPT manufacturing site highlights the power of biopharma innovation and the strong partnerships we’ve built along the way.
With this investment and innovation, we’re helping to redefine what’s possible for the future of cancer care for patients everywhere.”
Proceed to the video attached to the post.
More posts featuring Chris Boerner.